Kairos Pharma Ltd. (NYSE American: KAPA) will take a prominent role at the 24th Annual Discovery on Target Drug Discovery Conference, scheduled for September 28 to October 1 in Boston, where President and Chief Scientific Officer Neil Bhowmick will present and moderate a discussion. The company's participation underscores its commitment to advancing oncology therapeutics that address drug resistance and immune suppression, a critical challenge in cancer treatment.
Bhowmick will moderate a breakout session on September 30 titled "Winning the Race against Cancer Therapy Resistance." This session will focus on Kairos Pharma's strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates. The approach is designed to revive the potential of therapies that have lost effectiveness due to resistance mechanisms, offering new hope for patients who have exhausted standard options.
Additionally, Bhowmick will deliver an oral plenary presentation on September 30 at 2:35 p.m. Eastern, highlighting KROS-101, a drug candidate targeting solid tumors. The presentation will center on KROS-101's targeting of GITR (Glucocorticoid-Induced TNF Receptor) to increase T-cell function and expand effector T-cells with anti-tumor activity. By modulating the immune system, KROS-101 aims to enhance the body's ability to fight cancer, representing a promising avenue in immunotherapy.
The significance of these presentations lies in their potential to reshape treatment paradigms. Cancer drug resistance is a major obstacle, leading to relapse and limited therapeutic options. Kairos Pharma's focus on structural biology to overcome resistance and immune suppression positions it at the forefront of efforts to develop next-generation cancer therapies. The company's lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
For investors, the conference provides a platform for Kairos Pharma to showcase its scientific progress and potentially attract partnerships or funding. The latest news and updates relating to KAPA are available in the company's newsroom at https://nnw.fm/KAPA. The full press release can be viewed at https://nnw.fm/DoHxL.
NetworkNewsWire (NNW), a specialized communications platform, is disseminating this announcement. NNW is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. Additionally, NNW offers editorial syndication to 5,000+ outlets and enhanced press release enhancement to ensure maximum impact.
Through its comprehensive services, including social media distribution and tailored corporate communications solutions, NNW helps companies like Kairos Pharma gain visibility and engage with investors and the public. As Kairos Pharma continues to advance its pipeline, its participation in the Discovery on Target conference could mark a pivotal moment in its journey to bring novel cancer therapies to market.
